Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CD8B
REST API REST API
Homo sapiens
CD8B is differentially expressed in 185 experiments: 70 organism parts: thymus, blood, ... (68 more);, 135 disease states: normal, control, ... (133 more);, 50 cell types 149 cell lines 24 compound treatments and 66 other conditions.
Synonyms CD8B1
Orthologs Q90769_CHICK (Gallus gallus)   A7YW30_BOVIN (Bos taurus)   Cd8b1 (Mus musculus)   Cd8b (Rattus norvegicus)   CD8B (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Ig-like, Ig_V-set_subgr
Gene Ontology Term plasma membrane, protein binding, extracellular region, transmembrane receptor protein tyrosine kinase signaling pathway, external side of plasma membrane, early endosome, integral to plasma membrane, immune response, cell surface, regulation of immune response, viral reproduction, coreceptor activity, MHC class I protein binding, T cell activation, T cell receptor complex, regulation of defense response to virus by virus
UniProt Accession Q496E2, Q53QL8, Q8TD28, B4E0Z8, B4E0F8, P10966, A0N2Q4, E9PD41, F5H878, F5H356
Search EB-eye ENSG00000172116
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-22152, E-GEOD-24147, E-GEOD-19480, E-MEXP-2197, ... (15 experiments)

Factor Value U/D Experiments
UACC812
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HL-60
2
E-MTAB-37, E-GEOD-5258
MCF-7
2
E-GEOD-5823, E-GEOD-20081
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
143 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, ... (29 experiments)

Factor Value U/D Experiments
CD8+ T cell
5
E-AFMX-5, E-GEOD-6740, E-TABM-145, E-GEOD-19069, E-MTAB-25 ... (5 experiments)
stromal cell
2
E-GEOD-10797, E-GEOD-1460
peripheral blood mononuclear cell
1
E-GEOD-3026
erythropoietic
1
E-GEOD-9894
undifferentiated cell
1
E-GEOD-21668
naive T cell
1
E-GEOD-1460
44 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2508, E-GEOD-15960, E-MEXP-2069, E-GEOD-2549, ... (40 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
rheumatoid arthritis
2
E-GEOD-7307, E-GEOD-1919
obesity
2
E-MTAB-62, E-GEOD-2508
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
colon carcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
129 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-GEOD-697, E-GEOD-5824, E-GEOD-3720, ... (15 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-GEOD-7400, E-GEOD-697
control
2
E-GEOD-3284, E-GEOD-5339
U0126
1
E-GEOD-697
TNF
1
1
E-GEOD-15205
bacterial endotoxin
1
E-GEOD-3284
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-GEOD-22148, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-22278, E-MEXP-1103, E-GEOD-837

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (31 experiments)

Infection
studied in E-GEOD-9723, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Phenotype
studied in E-GEOD-22309, E-GEOD-1460, E-GEOD-7114

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.349 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM